Yahoo · Oct 18, 2026
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?
The gene-editing biotech stock is down more than 12% this year.
NASDAQ · BEAM
Beam Therapeutics Inc.
Healthcare · Biotechnology
$27.23
Down-$1.61 (-5.58%)
Updated Nov 1, 2026, 1:47 AM
SID Score
5.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 2.79B
- P/E ratio
- -6.8
- Dividend yield
- 0.00%
- 52-week range
- $20.23 – $38.26
- Volume
- 1.5M
- Avg. volume
- 2.37M
Price performance · BEAM
BEAM price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
BEAM closed at $27.23 after 20 trading sessions, up 6.08% for the selected period.
- Last close
- $27.23
- Period change
- +6.08%
- Period low
- $23.47
- Period high
- $28.84
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $28.27 | $28.85 | $26.426 | $27.23 | 1.5M |
| Oct 29, 2026 | $28.72 | $29.7603 | $28.40 | $28.84 | 2M |
| Oct 28, 2026 | $24.61 | $28.86 | $24.50 | $28.78 | 5.01M |
| Oct 27, 2026 | $23.73 | $25.09 | $23.39 | $24.90 | 2.75M |
| Oct 26, 2026 | $24.00 | $24.11 | $23.65 | $23.79 | 1.4M |
| Oct 23, 2026 | $24.00 | $24.14 | $23.24 | $24.05 | 1.6M |
| Oct 22, 2026 | $24.385 | $25.29 | $24.00 | $24.56 | 1.38M |
| Oct 21, 2026 | $24.83 | $25.20 | $24.50 | $24.84 | 1.17M |
| Oct 20, 2026 | $24.00 | $25.06 | $23.61 | $24.93 | 1.48M |
| Oct 19, 2026 | $23.885 | $24.38 | $23.50 | $24.19 | 1.32M |
| Oct 16, 2026 | $24.56 | $24.56 | $23.16 | $23.47 | 1.65M |
| Oct 15, 2026 | $23.51 | $24.98 | $23.20 | $24.73 | 1.78M |
| Oct 14, 2026 | $24.13 | $24.26 | $23.28 | $23.65 | 1.66M |
| Oct 13, 2026 | $24.88 | $24.93 | $24.08 | $24.43 | 1.67M |
| Oct 12, 2026 | $25.63 | $26.09 | $24.935 | $25.13 | 1.41M |
| Oct 9, 2026 | $24.72 | $26.225 | $24.55 | $25.70 | 1.8M |
| Oct 8, 2026 | $24.26 | $24.69 | $23.91 | $24.60 | 2.43M |
| Oct 7, 2026 | $24.635 | $25.37 | $24.45 | $24.77 | 2.34M |
| Oct 6, 2026 | $26.80 | $26.94 | $24.865 | $25.23 | 2.52M |
| Oct 5, 2026 | $24.48 | $26.04 | $23.83 | $25.67 | 2M |
Latest BEAM news
The latest Smart Investors Daily articles mentioning BEAM.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BEAM research
Overview
Company profile and research snapshot.
Company profile
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $38.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | Canaccord Genuity | Buy | — |
| Oct 28, 2026 | Wedbush | Outperform | — |
| Oct 15, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 14, 2026 | Wedbush | Outperform | — |
| Sep 9, 2026 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 15, 2026
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.
Benzinga · Oct 14, 2026
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target
Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.
Yahoo · Oct 13, 2026
Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress
BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent Improvements in Key GSDIa Endpoints Safety Profile of BEAM-301 Consistent with LNP-based Therapies Beam to Host Investor Webcast on Tuesday, October 27, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology co
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
